Cryoport, Inc. (CYRX)

Mixed fundamentals: solid liquidity and improving operating trends, but continuing operations are still unprofitable and free cash flow has been negative. The company’s net-cash balance sheet helps mitigate the December 2026 convertible note maturity, but the stock still depends on demonstrating sustained GAAP profitability and better capex discipline.

CYRX is in post-Q2-results digestion (mixed read: revenue beat but continued loss while guidance was reiterated), with incremental bullish sell-side/price-target commentary being offset by CEO insider-selling headlines. Media tone over the last ~14 days is mildly positive/neutral, but the 30–90d baseline is too sparse for a determinate sentiment delta; moderate red-flag cap applied due to conflicting in-window signals.

Bullish. CYRX (17.02) closed above its entire moving-average stack — SMA20 16.12, SMA50 15.79, SMA200 12.15 — with a bullish EMA stack (EMA9 16.29 > EMA21 16.04) and a freshly positive, expanding MACD (line 0.22 > signal 0.11, histogram +0.11). RSI14 64.14 is bullish without being overbought, and the stock has posted five consecutive up sessions off the 09-14 low (15.39 → 17.05), now pressing the 52-week high of 17.20 (08-21). Up-day volume is expanding (09-18: 777K shares vs ~500K recent average; 20-day dollar volume ~$8.5M). Weaknesses: ADX 16.71 (young trend, not yet confirmed strong) and Williams %R −3.95 (short-term stretched after +10.8% in five sessions) argue for a trigger above the prior high rather than chasing at the close. Score 4: strong setup with the weak-ADX/stretch caveat.